{"DataElement":{"publicId":"3462265","version":"1","preferredName":"Chronic Graft Versus Host Disease Immunosuppression Stratification Category","preferredDefinition":"Stratification classification to signify the intensity of immunosuppression in an individual with chronic Graft Versus Host Disease (GVHD).","longName":"CGVHD_IMM_STRAT_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"3462260","version":"1","preferredName":"Chronic Graft Versus Host Disease Immunosuppression Stratification Intensity","preferredDefinition":"A syndrome of immologically mediated tissue damage occurring following allogeneic transplant and may affect multiple organs with manifestations similar to autoimmune diseases.  Onset is usually within three years of transplantation or immunologic manipulation._An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response._The process of classifying patients into strata as part of the randomization process or for purposes of data analysis._The degree or magnitude of strength, energy, or feeling.","longName":"CGVHD_IMM_SRT_INT","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"3462257","version":"1","preferredName":"Chronic Graft Versus Host Disease Immunosuppressive Effect","preferredDefinition":"A syndrome of immologically mediated tissue damage occurring following allogeneic transplant and may affect multiple organs with manifestations similar to autoimmune diseases.  Onset is usually within three years of transplantation or immunologic manipulation.:An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response.","longName":"C4981:C40913","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Graft Versus Host Disease","conceptCode":"C4981","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunosuppressive Effect","conceptCode":"C40913","definition":"An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0B0DBF3-FF3E-CE57-E040-BB89AD430C3E","latestVersionIndicator":"Yes","beginDate":"2012-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-23","modifiedBy":"ONEDATA","dateModified":"2012-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3462258","version":"1","preferredName":"Stratification Intensity","preferredDefinition":"The process of classifying patients into strata as part of the randomization process or for purposes of data analysis.:The degree or magnitude of strength, energy, or feeling.","longName":"C25689:C25539","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stratification","conceptCode":"C25689","definition":"The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intensity","conceptCode":"C25539","definition":"The degree or magnitude of strength, energy, or feeling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0B0DBF3-FF4F-CE57-E040-BB89AD430C3E","latestVersionIndicator":"Yes","beginDate":"2012-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-23","modifiedBy":"ONEDATA","dateModified":"2012-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0B0DBF3-FF60-CE57-E040-BB89AD430C3E","latestVersionIndicator":"Yes","beginDate":"2012-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3462262","version":"1","preferredName":"Chronic Graft Versus Host Disease Immunosuppression Effect Stratification Category","preferredDefinition":"A syndrome of immologically mediated tissue damage occurring following allogeneic transplant and may affect multiple organs with manifestations similar to autoimmune diseases.  Onset is usually within three years of transplantation or immunologic manipulation._An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response._The process of classifying patients into strata as part of the randomization process or for purposes of data analysis._Category; used informally to mean a class of things.","longName":"CGVHD_IMM_SRT_CAT","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"7","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"High","valueDescription":"High Intensity Immunosuppression Effect","ValueMeaning":{"publicId":"3462264","version":"1","preferredName":"High Intensity Immunosuppression Effect","longName":"3462264","preferredDefinition":"An elevated level or position or degree; greater than normal in degree or intensity or amount.: The degree or magnitude of strength, energy, or feeling.: An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High","conceptCode":"C25227","definition":"An elevated level or position or degree; greater than normal in degree or intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Intensity","conceptCode":"C25539","definition":"The degree or magnitude of strength, energy, or feeling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunosuppressive Effect","conceptCode":"C40913","definition":"An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0B0DBF3-FFC5-CE57-E040-BB89AD430C3E","latestVersionIndicator":"Yes","beginDate":"2012-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0B0DBF3-FFDE-CE57-E040-BB89AD430C3E","beginDate":"2012-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-23","modifiedBy":"ONEDATA","dateModified":"2012-05-23","deletedIndicator":"No"},{"value":"Low","valueDescription":"Low Intensity Immunosuppression Effect","ValueMeaning":{"publicId":"3462263","version":"1","preferredName":"Low Intensity Immunosuppression Effect","longName":"3462263","preferredDefinition":"A minimum level or position or degree; less than normal in degree or intensity or amount.: The degree or magnitude of strength, energy, or feeling.: An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Low","conceptCode":"C54722","definition":"A minimum level or position or degree; less than normal in degree, intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Intensity","conceptCode":"C25539","definition":"The degree or magnitude of strength, energy, or feeling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunosuppressive Effect","conceptCode":"C40913","definition":"An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0B0DBF3-FF9E-CE57-E040-BB89AD430C3E","latestVersionIndicator":"Yes","beginDate":"2012-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0B0DBF3-FFB7-CE57-E040-BB89AD430C3E","beginDate":"2012-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-23","modifiedBy":"ONEDATA","dateModified":"2012-05-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3462261","version":"1","preferredName":"Chronic Graft Versus Host Disease Immunosuppressive Effect Stratification Category","preferredDefinition":"A syndrome of immologically mediated tissue damage occurring following allogeneic transplant and may affect multiple organs with manifestations similar to autoimmune diseases.  Onset is usually within three years of transplantation or immunologic manipulation.:An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response.:The process of classifying patients into strata as part of the randomization process or for purposes of data analysis.:Category; used informally to mean a class of things.","longName":"C4981:C40913:C25689:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Graft Versus Host Disease","conceptCode":"C4981","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Immunosuppressive Effect","conceptCode":"C40913","definition":"An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stratification","conceptCode":"C25689","definition":"The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0B0DBF3-FF76-CE57-E040-BB89AD430C3E","latestVersionIndicator":"Yes","beginDate":"2012-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-23","modifiedBy":"ONEDATA","dateModified":"2012-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0B0DBF3-FF87-CE57-E040-BB89AD430C3E","latestVersionIndicator":"Yes","beginDate":"2012-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-23","modifiedBy":"REEVESD","dateModified":"2016-05-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"cGVHD immunosuppression Strat","type":"Preferred Question Text","description":"cGVHD immunosuppression Stratification","url":null,"context":"CCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C0B0DBF3-FFE8-CE57-E040-BB89AD430C3E","latestVersionIndicator":"Yes","beginDate":"2012-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-23","modifiedBy":"REEVESD","dateModified":"2015-05-19","changeDescription":"Created for NCI CCR clinical trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}